Skip to content
Catalyst

coenzyme Q10Finding

Coenzyme Q10 decreases all-cause mortality

lowersModerate evidenceFinding

01 · The sentence it was drawn from

“All-cause mortality was lower in the CoQ10 group, 10 (9%) patients vs. 24 (20%) patients in the placebo group, corresponding to a relative reduction of 53% (p = 0.040).”
Quoted verbatim from Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group analysis of the Q-SYMBIO randomized double-blind trial.
This finding among the 158 findings on its endpoint

coenzyme Q10

All-cause mortality

lowers

Who
European sub-population (n=231) of the Q-SYMBIO trial, moderate-to-severe chronic heart failure, on standard HF therapy in both arms, long-term (2-year) follow-up
Dose studied
CoQ10 (Ubiquinone) 300 mg/day added to standard heart failure therapy

Moderate evidencePMID 30835327 · 2019

02 · The study

Study
RCT
Duration
not reported

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M3RHFZM3H2AFX8D7PGJPA93C